Enliven Takes Precision Oncology Ambitions Public In Merger With Imara
The planned all-stock transaction will enable Enliven to take over Imara’s Nasdaq listing with cash runway into 2026. Imara shareholders get contingent value rights tied to sold-off top candidate tovinontrine.
You may also be interested in...
California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.
The deal focuses on the HER2-targeting bispecific antibody zanidatamab, in development for multiple solid tumor indications expressing HER2.
Sio Gene, Genocea, Solid Biosciences, Saniona and Black Diamond join First Wave, Zosano, Vallon, Finch, Magenta, ProQR and Imara on the growing list of biopharma firms reducing headcount to make their cash last until valuations return to a level that may support new fundraising.